YOU ARE HERE:
Changing treatments news
page  of 6
 
Headline
Date
  Does tenofovir increase the risk of efavirenz-associated liver side-effects?
09.05.08
  Dual class drug resistance present in two-thirds of South African HIV cohort on failing ART
05.05.08
  Clinical monitoring as effective as CD4 count and viral load for deciding when to switch to second-line ART in poor countries
25.04.08
  ART recommended for all with CD4 counts below 350, say South African doctors
17.04.08
  Start anti-HIV treatment with a CD4 cell count of 350 with efavirenz and Truvada, say draft British guidelines
01.04.08
  CROI: Risk of second virological failure has declined since 1996, but risk of death remains stable
07.02.08
  WHO expert panel wants fewer second-line ART choices
31.01.08
  Kaletra monotherapy studies yield conflicting results
28.01.08
  Less risk of AIDS for patients with low CD4 cell count and no treatment options who stay on failing therapy
25.01.08
  Raltegravir now available for UK patients
24.01.08
  Factors affecting HIV therapy choice in women have changed
23.01.08
  EACS: Switching to atazanavir maintains viral suppression, even in patients with protease resistance
31.10.07
  EACS: Nevirapine studies highlight new first-line uses
31.10.07
  EACS: One in five UK patients remains on failing therapy for over a year
29.10.07
  Undetectable viral load is goal for all, together with earlier treatment, say new European treatment guidelines
25.10.07
  Return of nelfinavir's European license recommended
21.09.07
  ICAAC: Gains in limb fat and CD4 counts continue three years after switching from d4T to tenofovir
21.09.07
  ICAAC: Maraviroc failures associated with shifts from R5-tropic to mixed or X4-tropic HIV
20.09.07
  ICAAC: In NNRTI-based regimens, stepwise discontinuation minimises risk of antiretroviral resistance
19.09.07
  ICAAC: Best response to elvitegravir seen when used with T-20 and other active agents
19.09.07

page  of 6